New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:28 EDTONTYOncothyreon price target raised to $6 from $3 at Stifel
After speaking with a breast cancer physician consultant, Stifel thinks that Oncothyreon's ARRY-380 could be used to treat cancer that has spread from the breast to the central nervous system. The firm thinks that this indication could generate $47M of revenue for the company in 2022, and keeps a Buy rating on the stock.
News For ONTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
08:50 EDTONTYOncothyreon raises $40M in common stock and preferred stock offerings
Subscribe for More Information
September 17, 2014
18:29 EDTONTYOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTONTYOncothyreon fiels to sell common stock and convertible preferred stock
Oncothyreon announced that it intends to offer and sell shares of its Common Stock and Series A Convertible Preferred Stock in separate but concurrent underwritten public offerings. The Series A Convertible Preferred Stock is non-voting and convertible into shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. Cowen and Company, LLC is acting as the sole book-running manager in the offerings.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use